PINTA 745

Drug Profile

PINTA 745

Alternative Names: AMG 745; PINTA745

Latest Information Update: 11 Apr 2016

Price : $50

At a glance

  • Originator Amgen
  • Developer Amgen; Atara Biotherapeutics
  • Class Antibodies; Recombinant fusion proteins
  • Mechanism of Action Myostatin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Bone disorders; Muscular atrophy; Nutrition disorders

Most Recent Events

  • 01 Jan 2016 Pinta Biotherapeutics completes a phase I/II trial for Nutritional disorders in USA (NCT01958970)
  • 14 Dec 2015 Discontinued - Phase-I/II for Nutritional disorders in USA (IV)
  • 31 Aug 2015 Atara Biotherapeutics completes enrolment in its phase I/II trial for Nutritional disorders in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top